4-Octyl itaconate reduces influenza A replication by targeting the nuclear export protein CRM1

J Virol. 2023 Oct 31;97(10):e0132523. doi: 10.1128/jvi.01325-23. Epub 2023 Oct 12.

Abstract

Itaconate derivates, as well as the naturally produced metabolite, have been proposed as antivirals against influenza virus. Here, the mechanism behind the antiviral effects of exogenous 4-octyl itaconate (4-OI), a derivative of itaconate, against the influenza A virus replication is demonstrated. The data indicate that 4-OI targets the cysteine at position 528 of the CRM1 protein, resulting in inhibition of the nuclear export of viral ribonucleoprotein complexes in a similar manner as previously described for other selective inhibitors of nuclear export. These results postulate a mechanism not observed before for this immuno-metabolite derivative. This knowledge is helpful for the development of derivatives of 4-OI as potential antiviral and anti-inflammatory therapeutics.

Keywords: 4-OI; CRM1; antiviral; influenza virus; itaconate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Active Transport, Cell Nucleus
  • Antiviral Agents* / pharmacology
  • Exportin 1 Protein* / metabolism
  • Humans
  • Influenza, Human*
  • Nuclear Proteins / metabolism
  • Succinates* / pharmacology
  • Virus Replication* / drug effects

Substances

  • 4-octyl itaconate
  • Antiviral Agents
  • Nuclear Proteins
  • Succinates
  • XPO1 protein, human
  • Exportin 1 Protein